Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1637)	12/27/2005 8:02:39 AM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma "neutral" Tuesday, December 27, 2005 3:18:58 AM ET Robert W. Baird NEW YORK, December 27 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $20. In a research note published this morning, the analysts mention that although the company witnessed robust Aloxi sequential sales growth of 43% in November, the sales performance in October was extremely sluggish. According to the analysts, in order to meet the low end of MGI Pharma’s Aloxi sales guidance of $250 million-$260 million, Aloxi’s sales performance in December would have to be fairly strong.